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Pharmacokinetics of Ciprofloxacin in Elderly Patients 
F. Kees a , K . G . Naber ' \ G . P. Meyc r c , and H . Grobecker 1 
Summary: For perioperative prophylaxis 200 mg ciproflox-
acin were administered as a short intravenous infusion to 17 
patients aged 57—84 years before transurethral resection 
(TUR-P) or transvesicular enucleation (TVP) of the prostate. 
13 patients were injected simultaneously with 2.5 g ioxital-
amic acid i. v. to determine the kidney function. In 11 patients 
the plasma concentrations were assayed and the pharmaco-
kinetic parameters calculated. At the end of infusion the con-
centrations of ciprofloxacin in plasma reached 4.2 ± 0.8 pg/ 
ml and decreased after a fast distribution period (plasma half-
life 0.20 ± 0.09 h) with a terminal half-life of 4.2 ± 1.3 h 
to 0.2 ± 0.09 pg/ml after 10 h. The apparent volume of dis-
tribution in steady state was 183 ± 45 % of body wheight, 
the plasma clearance 45 7 + 146 ml7min770 kg. The average 
concentrations in prostatic adenoma tissue were at all sam-
pling times higher (2fold) than in plasma. The mean con-
centrations in prostatic secretion were about half of the re-
spective plasma concentrations. High concentrations of the 
concomitantly administered ioxitalamic acid in prostatic se-
cretion are considered as an indicator of urinary contami-
nation. In those patients high ciprofloxacin concentrations in 
prostatic secretion are not reliable. 
Zusammenfassung: Pharmakokinetik von Ciprofloxacin bei 
älteren Patienten 
17 Patienten im <4lter von 57—84 Jahren erhielten 200 mg 
Ciprofloxacin als intravenöse Kurzinfusion (30 min) im Rah-
men der perioperativen Prophylaxe vor transurethraler Re-
sektion (TUR-P) bzw. transvesikularer Enukleation (TVP) 
der Prostata. Bei 13 Patienten wurden gleichzeitig 2,5 g 
loxitalaminsäure injiziert, um die Nierenfunktion zu bestim-
men. Bei 11 Patienten wurden die Plasmakonzentrationen 
bis 10 h nach Injektion bestimmt und daraus die pharma-
kokinetischen Parameter berechnet. Die Konzentrationen von 
Ciprofloxacin im Plasma betrugen am Ende der Infusion 
4,2 ± 0,8 pg 7ml und fielen nach einer schnellen Verteilungs-
phase (Halbwertszeit 0.20 ± 0.09 h) mit einer Eliminations-
halbwertszeit von 4.2 ± 1.4 h auf 0,20 ± 0,09 ug/ml nach 
10 h ab. Das scheinbare Verteilungsvolumen im steady-state 
betrug 183 ± 45 % des Körpergewichts, die Plasma-Clea-
rance 457 ± 146 ml/min770 kg. Die Konzentrationen im 
Prostataadenomgewebe waren bei allen Patienten höher, im 
Mittel etwa doppelt so hoch wie die gleichzeitigen Plasma-
konzentrationen. Sie fielen parallel zu diesen ab, waren aber 
bis 2,5 h nach Applikation noch höher als 1 pg/g. Die Kon-
zentrationen im Prostatasekret betrugen etwa 20—100 % der 
gleichzeitigen Plasmakonzentrationen. Dabei wurde ange-
nommen, dajl hohe Konzentrationen von loxitalaminsäure 
im Prostatasekret auf Kontamination mit Urin hindeuten, 
weshalb die entsprechenden Ciprofloxacin-Konzentrationen 
als unzuverlässig eliminiert wurden. 
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1. Introduction 
Ciprofloxacin is a new quinolonc carboxylic acid with a 
broad antibacterial spectrum against gram-positive and 
gram-negative bacteria (Cullmann et al. 1984, Sanders et al. 
1987). A variety of publications deal with the plasma phar-
macokinetics and tissue penetration of ciprofloxacin after 
oral administration, but a few only report on intravenous 
administration (c.f. Bergan 1987, Sörgel ct. al 1987). The 
present study was performed to investigate the plasma phar-
macokinetics of ciprofloxacin in elderly urological patients 
after intravenous administration and its penetration into 
prostatic adenoma tissue and secretion. Ioxitalamic acid, a 
renal contrast medium, was administered simultaneously as 
a marker of kidney function, and to detect possible urinary 
contamination of prostatic secretion. 
2. Materials and methods 
2.1. Patients, administration and sampling 
14 patients aged 57—84 years (median 74 years) with a body weight 
of 52—80 kg (median 72 kg), a height of 155—175 cm (median 168 
cm), serum creatinine of 0.8—1.9 mg/dl (median 1.0 mg/dl), under-
going transurethral resection of the prostate (TUR-P) were admin-
istered intravenously with 200 mg ciprofloxacin as a 20—25 min 
infusion for perioperative antibiotic prophylaxis. Immediately be-
fore ciprofloxacin administration, 2.5 g ioxitalamic acid (5 ml Tc-
lebrix"; N 300) was injected intravenously. Before administration, 
15 min after start of the ciprofloxacin infusion, al the end, and after 
0.17. 0.33, 0.50, 0.75, 1.0, 1.5, 2, 3, 4, 6, 8 and 10 h, venous blood 
(ammonium-heparin Mono vetted Sarstedt, Nümbrecht, FR Ger-
many) was withdrawn from a contralateral arm vein through an in-
dwelling catheter (Braunüle, Braun, Melsungen, FR Germany). 1 — 
2.5 h after start of the ciprofloxacin infusion, immediately before 
TUR-P , prostatic secretion was obtained by massage of the prostate, 
if possible. During surgery, tissue samples of the left, median and 
right lobe of the prostate were taken for determination of tissue con-
centrations. In addition, in three patients (no. 16—18, 85, 76, 81 
years, 162, 170, 155 cm, 61, 70, 86 kg) undergoing T V P 16-18 h 
after ciprofloxacin infusion, prostatic adenoma tissue and secretion 
(squeezing out the enucleated tissue) was obtained. 
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Fig. 1: Chromatograms o f plasma (A, B). and prostatic adenoma tissue (C) of 
a pal ienl (no. 10), before (A, a) and 1.5 h (B, b; C , c) after intravenous admin-
istration o f 200 mg ciprofloxacin and 2.5 g ioxitalamic acid. A — C : Fluores-
cence at ex/em 280/445 nm. a—c: Absorbancc al 254 nm. Abbr.: IS, internal 
standard, norfloxacin; C P R , ciprofloxacin; M l and M X are metabolites of Ci-
profloxacin. IXT, ioxitalamic acid. 
2.2. Analysis 
2.2.1. Reagents and chemicals 
Ciprofloxacin with the respective metabolites, M l , M2, M3, M4, 
and norfloxacin were supplied by the respective manufacturers. Iox-
italamic acid (5-acctamido-N-(2-hydroxy-cthyl)-2,4,6-triiodo-iso-
phtalamic acid) and as diagnostic agent meglumine ioxitalamate (Te-
lebrix N 300) were obtained from Byk Gulden (Konstanz, FR Ger-
many). Tetrabutylammonium hydrogensulfate was purchased from 
Fluka (Neu Ulm, FR Germany), all other chemicals (analytical or 
H P L C grade) from E. Merck (Darmstadt, FR Germany). Water was 
purified with a Milli-Q water purification system (Millipore, Esch-
born, FR Germany). 
2.2.2. Chromatographic system 
All samples were stored al —70 °C until analysis and assayed by high-
performance liquid chromatography (HPLC) employing a solvent 
delivery system M 6000A, an autosampler WISP 710B, an integra-
tor M 730, and a system controller M 720 (all from Millipore Waters-
Chromatography, Eschborn, FR Germany). A fluorescence detector 
was used (F 1000, ex. 280 nm, em 445 nm, Merck-Hitachi, Darm-
stadt, FR Germany) for the quinolones, and in series a photometric 
detector (M 440, 254 nm, Millipore Walcrs-Chromatography) for 
ioxitalamic acid combined with an integrator D 2000 (Merck-Hi-
tachi, Darmstadt, FR Germany). For separation, a Novapak® CI8 
column (i.d. 150x4 mm, Millipore Waters-Chromatography) was 
used. The mobile phase consisted of 1000 ml water, 2.0 g tetrabu-
tylammonium hydrogensulfate, 2.0 ml 87 % o-phosphoric acid, and 
100 ml acetonitrilc. Chromatograms are shown in Fig. 1. 
2.3. Sample treatment 
Plasma (500 ul) was mixed with 100 ul internal standard (10 ug/ml 
norfloxacin in 1.0 % Na 2 EDTA, pH 7.0) and 2.0 ml methanol. After 
standing for 15—20 min at 4 °C the precipitated protein was sepa-
rated by ccntrifugation (10 min, 4500 g). Prostatic secretion (100— 
200 ul) was treated similarly. Tissue was divided in two parts (200— 
600 mg) and dissected (20—30 mg pieces). One part was treated for 
5 min in a stomacher no. 80 (Kleinfeld, Hannover, FR Germany) 
with 10 volumes 0.1 mol/1 sodium phosphate, pH 7.0 (2 mmol/1 
Na 2 EDTA, 100 ng/ml internal standard norfloxacin), and 500 ul of 
the cluate was ultracentrifuged (Centrisart 1, cut off 20,000, Sarto-
rius, Göttingen, FR Germany. Adsorption of the compounds at the 
ultrafiltration membrane did not occur). The other part was homo-
genized in 10—20 volumes of a mixture of 500 ml water, 500 ml 
methanol, 10 ml 70 % perchloric acid, 1 ml 87 % o-phosphoric acid 
containing 100 ng/ml internal standard norfloxacin (homogeniza-
lion: 1 — 1.5 min, cooling with ice, ultra lurrax homogenizertypeTP-
18-10 with slick SN 25N-10G, IKA, Staufen, FR Germany). After 
standing for 15—20 min at 4 °Cthc mixture was centrifuged( 10 min, 
4500 g). 5—10 ul of the respective supernatants were injected onto 
the column. 
2.4. Evaluation of the assay 
Linearity was checked in the range 0.2—5 ug/ml (ciprofloxacin), 
0.02—0.05 ug/ml (M1) and 10—250 ug/ml (ioxitalamic acid) and was 
found satisfactory (coefficient of correlation better than 0.9990). 
The recovery of ioxitalamic acid from plasma was quantitative, that 
of norfloxacin (internal standard) and ciprofloxacin equal and 
amounted to about 90%, whereas the recovery of metabolite Ml 
was 70 % only. The recovery of the internal standard norfloxacin 
from patients plasma was 93.1 ± 1.5%, from tissue 82.6 ± 5.2 
(stomaching) and 87.2 ± 5.2 (ultra turrax). Accuracy and reproduc-
ibility (3 assay days, 9 specimens) for spiked control plasma speci-
mens (5, 2, 0.5 ug/ml for ciprofloxacin, 0.5, 0.2, 0.05 ug/ml for Ml 
and 50, 20, 5 ug/ml for ioxithalamic acid) was 100.8 ± 2.5% for 
ciprofloxacin, 104.9 ± 1.8 % for M l , and 98.4 ± 3.5 % for ioxita-
lamic acid. The known metabolites of ciprofloxacin, M2, M3, M4, 
could not be quantified by the analytical procedure because of their 
differing chromatographic and fluorescing properties (c.f. Scholl et 
al. 1987). 
2.5. Pharmacokinetic calculation 
The plasma level data were analysed by the open, two-compartment 
model using standard pharmacokinetic equations. Details of the 
procedure arc given elsewhere (Kccs et al. 1985). 
3. Results 
The mean plasma concentrations of ciprofloxacin and ioxi-
talamic acid are shown in Fig. 2, the mean values of cipro-
floxacin including M l and the unknown metabolite M X , 
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Fig, 2: Plasma conccnirations (mean, standard deviation) of ciprofloxacin ( • ) 
and ioxitalamic acid (•) after intravenous infusion (0.5 h) o f 200 mg cipro-
floxacin in 11 elderly urological patients and bolus injection of 2.5 g ioxitalamic 
acid to 10 patients. (Patient 8 was not injected with ioxitalamic acid, because 
o f possible allergic side effects.) 
Table 1: Concentrations (mean, standard deviation) o f ciprofloxacin and the 
metabolites M I and M X in plasma of 11 elderly patients after intravenous 
administrat ion of 200 mg ciprofloxacin. 
T ime Ciprof loxacin M l M X " 
(h) (ug/ml) (ng/ml) (" ng/ml") 
- 0.25 3.63 ± 0.91 5.30 ± 3.54 
0.00 : ' 4.15 ± 0.79 8.44 ± 3.43 47 ± 31 
0.17 2.15 ± 0.49 9.32 ± 2.60 71 ± 38 
0.33 1.73 ± 0.36 10.2 ± 3.09 114 ± 81 
0.50 1.52 ± 0.33 10.8 ± 2.96 127 ± 60 
0.75 1.20 ± 0.26 10.3 ± 3.33 156 ± 61 
1.0 1.09 ± 0.23 9.81 ± 3.24 175 ± 67 
1.5 0.87 ± 0.16 8.88 ± 2.71 191 ± 66 
2.0 0.76 ± 0 . 1 8 8.33 ± 3 . 1 2 186 + 67 
3.0 0.61 ± 0.16 7.07 ± 2.46 159 ± 55 
4.0 0.53 ± 0.16 6.45 ± 2.09 142 ± 56 
6.0 0.38 ± 0 . 1 5 5.50 ± 1.67 113 ± 49 
8.0 0.26 ± 0 . 1 0 4.83 ± 2.11 92 ± 46 
10.0 0.20 ± 0.09 3.88 ± 1.40 76 ± 4 6 
Apparent concentrations in terms o f ciprofloxacin units. 
E n d of ciprofloxacin infusion. 
evaluated as the parent compound ciprofloxacin, are de-
picted in Table 1. The mean maximum levels of ciproflox-
acin at the end of the infusion were 4.15 ± 0.79 ug/ml, 1 h 
later on 1.09 + 0.23 ug/ml and after 10 h 0.20 ± 0.09 ug/ 
ml . Dur ing the same period the plasma levels of ioxitalamic 
acid decreased from 159.4 ± 15.2 ug/ml to 10.5 ± 7.9 jug/ 
ml . As can be seen, the mean maximum plasma levels of the 
metabolite M l were reached 0.5 h after the end o f the c i -
profloxacin infusion amounting to less than 1 % of the si-
multaneous ciprofloxacin concentrations, whereas the un-
known metabolite reached its maximum 1.0 h later. 
The estimated pharmacokinetic parameters of ciprofloxacin 
and ioxitalamic acid are given in Table 2. The mean steady 
state volume of ciprofloxacin was calculated about twofold 
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Fig. 3: Correlat ion between the plasma clearance (70 kg) o f ciprofloxacin ( C P R ) 
and ioxitalamic acid (IXI) in elderly urological patients. The numbers mark 
the patients. 
Table 2: Pharmacokinetic parameters o f ciprofloxacin (Table 2a) and ioxital-
amic acid (Table 2b) in elderly urological patients after intravenous adminis-
tration o f 200 mg ciprofloxacin as half an hour infusion, and bolus injection 
of 2.5 g ioxitalamic acid. Abbr. : S D , standard deviation; V t . , volume of the 
central compartment; V s s , steady state volume of distr ibution; % b.w., percent-
age o f body weight; A U C , area under the plasma concentration-time curve; 
CI,70kg, total body clearance normalized to 70 kg b.w.; t„, plasma half-life of 
the fast distr ibution phase; t„, terminal plasma half-life. 
Table 2a 
Pat. 
B.w. 
(kg) 0) 
V s s 
(1) 
V s s 
%b.w. 
A U C 
(mg/1 h) 
CI, 
(ml/ 
min) 
Cl,70kg 
(ml/ 
min) 
t,« 
(h) (h) 
1 56 30.3 97.8 175 6.51 512 640 0.20 2.85 
i 67 22.1 99.4 148 6.95 480 501 0.15 3.12 
3 65 23*0 95.3 147 5.58 597 643 0.13 2.45 
5 80 25.1 102 128 10.3 324 284 0.19 4.37 
6 78 26.1 120 154 7.52 443 398 0.15 3.80 
8 74 55.8 151 204 11.4 292 276 0.43 6.87 
9 77 35.7 151 196 6.73 495 450 0 13 4.02 
10 66 26.0 139 211 7.55 441 468 0.12 4.28 
11 52 41.8 146 281 7.86 424 571 0.19 4.55 
12 73 38.2 109 149 13.9 240 230 0.26 5.85 
13 75 64.2 165 220 5.52 604 564 0.25 3.63 
Mean 69 35.3 125 183 8.17 441 457 0.20 4.17 
S D 9 13.9 26 45 2.62 117 146 0.09 1.28 
Median 73 30.3 120 175 7.52 443 468 0.19 4.28 
M i n 52 22.1 95.3 128 5.52 240 234 0.12 2.45 
M a x 80 55.8 165 281 13.9 604 643 0.43 6.87 
Table 2b 
Pat. 
1 
2 
3 
5 
6 
9 
10 
11 
12 
13 
Mean 
S D 
Median 
M i n 
Max 
B.w. 
(kg) 
56 
67 
65 
80 
78 
77 
66 
52 
73 
75 
69 
9 
73 
52 
80 
V , 
0) 
12.4 
8.66 
8.99 
8.43 
9.26 
13.4 
12.0 
12.8 
11.0 
10.3 
10.7 
1.8 
11.0 
8.43 
12.8 
V s s 
(1) 
15.6 
14.2 
13.2 
16.7 
15.0 
18.0 
19.0 
16.7 
14.8 
14.9 
15.8 
1.8 
15.6 
13.2 
19.0 
V s s 
%b.w. 
27.9 
21.2 
20.3 
20.9 
19.2 
23.4 
28.8 
32.1 
20.3 
19.9 
23.4 
4.5 
21.2 
19.2 
32.1 
A U C 
(mg/I h) 
593 
540 
418 
888 
506 
440 
592 
677 
929 
379 
596 
188 
592 
379 
929 
CI, 
(ml/ 
min) 
67.3 
73.9 
95.6 
44.9 
78.8 
90.7 
67.4 
58.9 
43.0 
105 
72.6 
20.6 
73.9 
43.0 
105 
Cl ,70kg 
(ml/ 
min) 
84.1 
77.2 
103 
39.3 
70.7 
82.4 
71.5 
79.3 
41.2 
98.0 
74.7 
20.9 
79.3 
39.3 
103 
tu 
(h) 
0.59 
0.35 
0.48 
0.35 
0.39 
0.44 
0.59 
1.13 
0.42 
0.57 
0.53 
0.23 
0.48 
0.35 
1.13 
(h) 
2.93 
2.52 
2.00 
4.70 
2.53 
2.48 
3.75 
3.90 
4.15 
2.17 
3.10 
0.93 
2.88 
2.00 
4.70 
Note: Patient 8 was not injected with ioxitalamic acid because of possible 
allergic side effects. 
of the body weight, whereas that of ioxitalamic acid was in 
accordance with previous*results (Kees et al. 1985, Naber et 
al. 1986), about 20 % of the body wheight corresponding to 
the extracellular space. The mean plasma clearance of c i -
profloxacin was 457 ± 146 mI/min/70 kg b.w., that of ioxi-
talamic acid 74.7 + 20.9 ml/min/70 kg b.w., indicating 
slightly decreased renal function in the elderly patients. The 
plasma clearances were linear correlated with each other 
(Fig. 3). The half life of ciprofloxacin in the first distribution 
phase was markedly shorter (0.20 ± 0.09 h) than that of iox-
italamic acid (0.53 ± 0.23 h), but in the terminal phase 
somewhat longer (4.17 ± 1.29 h versus 3.10 ± 0.94 h). 
In Tabic 3 the concentrations of ciprofloxacin and ioxital-
amic acid obtained in prostatic adenoma tissue, secretion, 
and the concomitant plasma values are shown. The concen-
trations of the metabolites reached 0.5—2 % ( M l ) and 3— 
1 5 % ( M X ) of the respective ciprofloxacin concentration 
(not listed). Only mean values of the tissue levels are speci-
fied, because no significant difference could be found be-
tween the left, median and right lobe of the prostate. But it 
should be noted that intraindividually the concentrations in 
the three parts of the organ differed up to the factor 2, pre-
sumably mainly because of different composition of the tis-
sue slices. The correlation between the concentrations of c i -
profloxacin and ioxitalamic acid was satisfactory linear (ho-
mogenization by stomaching: r = 0.74; by ultra turrax: r = 
0.86). At all sampling times the tissue levels exceeded the 
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Fig. 4: Prostatic adenoma tissue over plasma ratio of ciprofloxacin in elderly 
urological patients after intravenous administrat ion of 200 mg ciprofloxacin. 
The numbers mark the patients. 
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Fig. 5: Prostatic secretion over plasma ratio o f ciprofloxacin in elderly urol-
ogical patients after intravenous administrat ion of 200 mg ciprofloxacin. The 
numbers mark the patients. 
concomitant plasma levels (Fig. 4). The median ratio was 
1.68 (range: 1.11—4.24) after stomaching and 2.18 (range: 
1.41—5.43) after ultra turrax homogenization. In prostatic 
secretion the concentrations of ciprofloxacin were generally 
lower than in plasma (Fig. 5). Assuming high concentrations 
of ioxitalamic acid as indicative for urinary contamination 
(Naber et al. , in press), patient 10, 12, and 15 have to be 
eliminated. The median concentration in the remaining six 
patients undergoing T U R - P was 45 % (range: 21—94 %) of 
the concomitant plasma concentration. In the three patients 
Table 3: Concentrations of ciprofloxacin and ioxitalamic acid in plasma, pro-
static adenoma tissue and prostatic secretion of elderly patients after intrave-
nous administration of 200 mg ciprofloxacin and 2.5 g ioxitalamic acid. (—.— 
= no sample or no drug administration; ST = stomaching, U T = ultra turrax 
homogenization). 
Pal . T i m e 
(h) 
Ciprof loxacin Ioxitalamic acid 
Plasma 
(ug/ml) 
Prostate 
Plasma 
(ug/ml) 
Prostate 
Seer, 
(ug/ml) 
Tissue 
Sccr. 
(^ig/rnl) 
Tissue 
S T 
(u-g/g) 
U T 
(üg/g) 
ST 
(ng/g) 
U T 
(ug/g) 
5 1.0 1.26 2.71 3.46 105 49.3 80.1 
11 1.0 1.07 1.01 4.54 5.81 113 9.1 74.9 83.5 
13 1.0 0.87 0.62 1.80 2.41 78.5 25.5 55.7 57.4 
7 1.5 0.65 — . — 2.18 2.61 77.3 —.— 51.4 45.1 
9 1.5 0.75 0.16 1.61 1.79 80.5 4.3 30.3 36.9 
10 1.5 0.80 0.96 1.05 1.41 98.9 64.3 31.7 35.3 
14 1.5 1.54 0.63 2.58 3.87 150 18.9 67.7 87.5 
1 2.0 0.68 —.— 1.14 1.95 I I I _ — 30.1 56.2 
2 2.0 0.65 _ 2.10 2.86 98.5 —.— 30.2 55.3 15 2.0 1.14 14.8 1.26 1.65 116 177 52.8 53.1 
3 2.5 0.55 0.14 0.89 1.02 90.8 16.3 14.4 29.2 
6 2.5 0.64 — . — 2.16 1.28 88.3 _ — 31.9 2 5 Ü 
8 2.5 0.82 0.39 1.32 1.19 
12 2.5 1.23 1.32 1.60 1.73 132 104 42.0 30.5 
17'» 16.0 0.072 0.058 0.096 0.129 
18" 17.0 0.087 0.042 0.108 0.115 
16" 18.0 0.230 0.273 0.436 0.466 
Transvesicular enucleation of the prostate 
undergoing T V P , where urinary contamination of tissue and 
secretion during sampling can be excluded, 16—18 h after 
drug administration the concentrations of ciprofloxacin in 
tissue were 180, 130, and 200%, respectively, and in pro-
static secretion 80, 50, and 120 % of the concomitant plasma 
concentration (Table 3). 
4. Discussion 
Ciprofloxacin is a quinolone carboxylic acid whose clear-
ance pathways in man include renal, as well as significant 
metabolic clearance with the formation of several metabo-
lites (c.f. Borner et al. 1984, Bergan 1987). Four of these 
have been identified in urine (Gau et al. 1986). Because of 
multiple clearance pathways for ciprofloxacin, the effect of 
declining renal function on overall serum clearance is diffi-
cult to predict. Therefore, in our investigation the patients 
were injected intravenously with ioxitalamic acid, a renal 
contrast medium, which is eliminated by glomerular filtra-
tion only (Kees et al. 1985). There was a good linear corre-
lation between the plasma clearances of ciprofloxacin and 
ioxitalamic acid, whereas only a bad linear correlation was 
found between the plasma clearances of ciprofloxacin and 
creatinine (Drusano et al. 1987). Our results confirm the su-
periority of intravenous ioxitalamic acid and similar com-
pounds as marker of renal function over measurement of 
creatinine. The intercept of the regression line with the y-
axis at positive values reveals the partial non-renal clearance 
of ciprofloxacin. 
O f the four known metabolites of ciprofloxacin in man (Gau 
et al. 1986), M l is simply to determine in plasma simulta-
neously with the parent compound because of its similar 
chromatographic behaviour and intense fluorescence (c.f. 
A w n i et al. 1987). Surprisingly, metabolite M X , which also 
exhibits favourable chromatographic and fluorescent behav-
iour, has been not yet mentioned (Gau et al. 1985, 1986). In 
a recent study (Myers and Blumer 1987) more attention is 
directed to the fluorescent metabolites of ciprofloxacin, but 
the metabolites are not all identified. Because of differing 
chromatographic procedures the compound M X , found in 
our work, cannot be assigned to any metabolite found by 
Myers and Blumcr (1987). Even i f the structure may not very 
differ from that of M l or ciprofloxacin iteself, quantification 
is not allowed, especially because of the very variable fluo-
rescence properties of ciprofloxacin and its metabolites 
(Scholl et al. 1987). Therefore, our data express only the per-
centage of M X in terms of ciprofloxacin fluorescence. Fur-
ther studies are necessary to elucidate the structure of me-
tabolite M X . 
Compared to pharmacokinetic results in young healthy vol-
unteers (c.f. Bergan 1987, Bergan et al. 1987) in the elderly 
patients the plasma clearance was decreased and half-life in-
creased at about 30 % (28 versus 40 1/h, 4.2 versus 3 h), like 
in patients with impaired renal function (Drusano et al. 
1987). Because of partial non-renal clearance of ciprofloxa-
cin, the differences were smaller than in the case of ioxital-
amic acid, whose mean clearance in the patients investigated 
was only 60 % of that in young volunteers (c.f. Kees et al. 
1985), and whose plasma half-life was prolonged at 70 %. 
Wi th respect to ioxitalamic acid, the plasma half life of ci-
profloxacin in the a-phase was shorter, indicating faster dis-
tribution of ciprofloxacin into several tissues. Accordingly, 
the highest levels in prostatic adenoma tissue were already 
found at the first sampling time, namely 1 h after start, i.e. 
about half an hour after the end of infusion. For periopera-
tive prophylaxis intravenous administration of ciprofloxa-
cin can be recommended because of reliable antibacterial 
tissue levels already 0.5—1 h after administration in contrast 
to oral administration (Dahlhoff 1987). In all cases the as-
sayed tissue concentrations exceeded the plasma levels both 
after stomaching and after ultra turrax homogenization, and 
d id not show the large variability found in a previous study 
(Dahlhoff 1987). Even i f by ultra turrax homogenization 
somewhat higher tissue levels were assayed, stomaching is 
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also a useful method for disintegrating prostatic tissue (c.f. 
Kees et al., in press). 
The concentrations in prostatic secretion were rather scat-
tered showing a secretion-plasma ratio of 0.2 to 13. When 
high concentrations of the simultaneously administered 
ioxitalamic acid were correctly taken as indicative for uri-
nary contamination, and therefore the three patients 10, 12 
and 15 were eliminated correctly, the plausible concentra-
tions of ciprofloxacin in prostatic secretion after single ad-
ministration are lower than in plasma. In prostatic adenoma 
tissue and secretion of the patients undergoing T V P , where 
contamination with urine during sampling can be excluded, 
the tissue-plasma and secretion-plasma ratios 16—18 h after 
ciprofloxacin administration were similar to those in the 
other patients. Accumulat ion was observed neither in tissue 
nor in secretion. Wi th regard to observations in healthy vol-
unteers where it was found difficult to obtain prostatic se-
cretion free of urine, especially after having voided (Naber 
et al., in press), we conclude that the high concentrations in 
prostatic secretion (up to 30fold the plasma concentration) 
12—24 h after oral administration of ciprofloxacin pub-
lished by Dahlhoff (1987) were presumably caused by uri-
nary contamination. 
In conclusion, after single intravenous injection of 200 mg 
ciprofloxacin in elderly patients the mean concentrations in 
prostatic adenoma tissue were doubled with respect to the 
concomitant plasma levels, and in prostatic secretion we ob-
served about half the plasma concentration. In the investi-
gated period up to 2.5 h after administration of ciprofloxa-
cin the tissue concentrations were above 1 ug/ml, high 
enough for use of intravenous ciprofloxacin for periopera-
tive prophylaxis during T U R - P . 
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